Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env-V2

The RV144 trial demonstrated 31% vaccine efficacy (VE) at preventing HIV-1 infection(1). Antibodies against the HIV-1 envelope variable loops 1 and 2 (V1/V2) domain correlated inversely with infection risk(2). We hypothesized that vaccine-induced immune responses against V1/V2 would selectively impa...

Descripción completa

Detalles Bibliográficos
Autores principales: Rolland, Morgane, Edlefsen, Paul T., Larsen, Brendan B., Tovanabutra, Sodsai, Sanders-Buell, Eric, Hertz, Tomer, deCamp, Allan C., Carrico, Chris, Menis, Sergey, Magaret, Craig A., Ahmed, Hasan, Juraska, Michal, Chen, Lennie, Konopa, Philip, Nariya, Snehal, Stoddard, Julia N., Wong, Kim, Zhao, Hong, Deng, Wenjie, Maust, Brandon S., Bose, Meera, Howell, Shana, Bates, Adam, Lazzaro, Michelle, O'Sullivan, Annemarie, Lei, Esther, Bradfield, Andrea, Ibitamuno, Grace, Assawadarachai, Vatcharain, O'Connell, Robert J., deSouza, Mark S., Nitayaphan, Sorachai, Rerks-Ngarm, Supachai, Robb, Merlin L., McLellan, Jason S., Georgiev, Ivelin, Kwong, Peter D., Carlson, Jonathan M., Michael, Nelson L., Schief, William R., Gilbert, Peter B., Mullins, James I., Kim, Jerome H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2012
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551291/
https://www.ncbi.nlm.nih.gov/pubmed/22960785
http://dx.doi.org/10.1038/nature11519

Ejemplares similares

Ejemplares similares